GRAIL's Q1 revenue rises 28% to $40.8M with 50% growth in Galleri test volume, plans Epic EHR integration.

GRAIL reported a 28% increase in total revenue to $40.8 million for Q1 2026, driven by a 37% rise in Galleri test revenue and a 50% increase in test volume to over 56,000. The company plans to integrate its Galleri cancer detection test into Epic's electronic health record platform to expand nationwide access by the end of 2026. Despite a net loss of $93.2 million, GRAIL improved its financial performance compared to last year and will present new clinical data at the 2026 ASCO Annual Meeting. This integration and ongoing clinical validation aim to boost adoption and early cancer detection capabilities.